2 results match your criteria: "Mugla Sitki Kocman University Training Research Hospital[Affiliation]"
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Future Oncol
March 2023
Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, 06800, Turkey.
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features.
View Article and Find Full Text PDFComparison of ETCO2 Value and Blood Gas PCO2 Value of Patients Receiving Non-invasive Mechanical Ventilation Treatment in Emergency Department.
SN Compr Clin Med
April 2021
Department of Emergency Medicine, Mugla Sitki Kocman University Training Research Hospital, Mugla, Turkey.
Article Synopsis
- Capnography measures carbon dioxide levels in breath, specifically focusing on the difference between pCO2 and ETCO2 during respiratory treatment.
- This study evaluated whether ETCO2 could substitute for pCO2 in patients undergoing non-invasive mechanical ventilation (NIMV) due to respiratory issues like cardiogenic edema or COPD.
- Findings showed significant differences between pCO2 and ETCO2 values in patients treated with NIMV, indicating that ETCO2 cannot replace pCO2 for monitoring these patients.